Thrombotic microangiopathy after kidney transplantation: diagnosis and management strategies
Open Access
- 24 January 2026
- journal article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (3)
Abstract
Thrombotic microangiopathy (TMA) is a pathological condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and ischemic organ dysfunction due to microvascular endothelial damage and thrombosis. It affects ∼0.8%–14% of kidney transplant recipients, and may manifest as either a recurrent or de novo disease. While systemic manifestations are commonly anticipated, kidney-limited TMA can also occur and is not rare. Histopathologic examination of allograft biopsies shows morphologic features indicating endothelial injury, and repeated episodes of TMA may result in coexisting acute and chronic lesions within the same patient. In transplant recipients, multiple triggers contribute to endothelial damage, including ischemia-reperfusion injury, antibody-mediated rejection, immunosuppressive agents (calcineurin and mTOR inhibitors), and infections. The risk is particularly important in individuals with genetic variants that dysregulate the alternative complement pathway. In de novo TMA, environmental triggers and transplant-related stressors play a central role, whereas genetic predisposition is the primary factor in recurrent cases. Notably, these mechanisms often overlap and may act synergistically. Recurrent atypical hemolytic uremic syndrome can successfully be managed with terminal complement inhibitors, and prophylactic use of eculizumab in the peri-transplant period has significantly reduced recurrence rates. Management of de novo TMA begins with the identification and removal of precipitating factors. In cases where no clear trigger is found, or when the disease proves refractory to conventional therapy, terminal complement inhibition may be an effective therapeutic option. The prognosis of recurrent TMA has improved substantially with the advent of complement targeting therapies but research is still needed to optimize management strategies.Keywords
This publication has 123 references indexed in Scilit:
- Thrombotic thrombocytopenic purpura induced by trimethoprim‐sulfamethoxazole in a Jehovah's witnessAmerican Journal of Hematology, 2007
- Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndromeProceedings of the National Academy of Sciences, 2007
- Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathyNephrology Dialysis Transplantation, 2006
- Outcome of Renal Transplantation in Patients with Non–Shiga Toxin–Associated Hemolytic Uremic SyndromeClinical Journal of the American Society of Nephrology, 2006
- Increased Risk of Thrombotic Microangiopathy in Patients Receiving a Cyclosporin–Sirolimus CombinationAmerican Journal of Transplantation, 2004
- Thrombotic microangiopathy after renal transplantation in the United StatesAmerican Journal of Kidney Diseases, 2003
- Thrombotic Micro-Angiopathy with Sirolimus-Based Immunosuppression: Potentiation of Calcineurin-Inhibitor-Induced Endothelial Damage?American Journal of Transplantation, 2003
- De novo thrombotic microangiopathy in renal transplant recipients: A comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathyAmerican Journal of Kidney Diseases, 2003
- Hemolytic Uremic Syndrome: Recurrence after Renal TransplantationMedicine, 2000
- FK506-ASSOCIATED THROMBOTIC MICROANGIOPATHYTransplantation, 1999